참고문헌 (255)

1. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley？ME, White DE, et al. : Tumor antigen-specific CD8 T cells infiltrating the？tumor express high levels of PD-1 and are functionally impaired. Blood？114 : 1537-1544, 2019 

2. Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D, et al. :？HER2-specific chimeric antigen receptor-modified virus-specific T cells？for progressive glioblastoma: a phase 1 dose-escalation trial. JAMA？Oncol 3 : 1094-1101, 2017 

   상세보기

3. Ajina A, Maher J : Prospects for combined use of oncolytic viruses and？CAR T-cells. J Immunother Cancer 5 : 90, 2017 

   상세보기

4. Alkins R, Burgess A, Kerbel R, Wels WS, Hynynen K : Early treatment？of HER2-amplified brain tumors with targeted NK-92 cells and focused ultrasound improves survival. Neuro Oncol 18 : 974-981, 2016 

5. Anderson AC, Joller N, Kuchroo VK : Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation.？Immunity 44 : 989-1004, 2016 

   상세보기

6. Avril T, Vauleon E, Hamlat A, Saikali S, Etcheverry A, Delmas C, et al. :？Human glioblastoma stem-like cells are more sensitive to allogeneic NK？and T cell-mediated killing compared with serum-cultured glioblastoma？cells. Brain Pathol 22 : 159-174, 2012 

7. Baba J, Watanabe S, Saida Y, Tanaka T, Miyabayashi T, Koshio J, et al. :？Depletion of radio-resistant regulatory T cells enhances antitumor immunity during recovery from lymphopenia. Blood 120 : 2417-2427, 2012 

   상세보기

8. Balch CM, Riley LB, Bae YJ, Salmeron MA, Platsoucas CD, von Eschenbach A, et al. : Patterns of human tumor-infiltrating lymphocytes in 120？human cancers. Arch Surg 125 : 200-205, 1990 

   상세보기

9. Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH : Intratumoral？LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 70 :？175-182, 1989 

   상세보기

10. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. : Tumor regression in cancer patients by very low doses of a T cell-engaging？antibody. Science 321 : 974-977, 2008 

11. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, et al. : Activation？of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.？Science 285 : 727-729, 1999 

    상세보기

12. Bielamowicz K, Fousek K, Byrd TT, Samaha H, Mukherjee M, Aware N,？et al. : Trivalent CAR T cells overcome interpatient antigenic variability in？glioblastoma. Neuro Oncol 20 : 506-518, 2018 

13. Billadeau DD, Upshaw JL, Schoon RA, Dick CJ, Leibson PJ : NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent？regulatory pathway. Nat Immunol 4 : 557-564, 2003 

    상세보기

14. Bougatef F, Quemener C, Kellouche S, Naimi B, Podgorniak MP, Millot？G, et al. : EMMPRIN promotes angiogenesis through hypoxia-inducible？factor-2alpha-mediated regulation of soluble VEGF isoforms and their？receptor VEGFR-2. Blood 114 : 5547-5556, 2009 

15. Brantley-Sieders DM, Fang WB, Hwang Y, Hicks D, Chen J : Ephrin-A1？facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial？growth factor in mice. Cancer Res 66 : 10315-10324, 2006 

    상세보기

16. Brocker T, Karjalainen K : Signals through T cell receptor-zeta chain alone？are insufficient to prime resting T lymphocytes. J Exp Med 181 : 1653-1659, 1995 

    상세보기

17. Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, et al. :？Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med 375 : 2561-2569, 2016 

    상세보기

18. Brown CE, Badie B, Barish ME, Weng L, Ostberg JR, Chang WC, et al. :？Bioactivity and safety of IL13Rα2-redirected chimeric antigen receptor？CD8+ T cells in patients with recurrent glioblastoma. Clin Cancer Res？21 : 4062-4072, 

19. Brown CE, Rodriguez A, Palmer J, Ostberg JR, Naranjo A, Wagner JR,？et al. : Off-the-shelf, steroid-resistant, IL13Rα2-specific CAR T cells for？treatment of glioblastoma. Neuro Oncol 24 : 1318-1330, 2022 

20. Brown CE, Warden CD, Starr R, Deng X, Badie B, Yuan YC, et al. : Glioma IL13Rα2 is associated with mesenchymal signature gene expression？and poor patient prognosis. PLoS One 8 : e77769, 2013 

21. Buchroithner J, Erhart F, Pichler J, Widhalm G, Preusser M, Stockhammer G, et al. : Audencel immunotherapy based on dendritic cells has no？effect on overall and progression-free survival in newly diagnosed glioblastoma: a phase II randomized trial. Cancers (Basel) 10 : 372, 2018 

    상세보기

22. Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J,？Petti AA, et al. : A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348 : 803-808,？2015 

    상세보기

23. Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, PostelVinay S, et al. : Hyperprogressive disease is a new pattern of progression？in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res 23 :？1920-1928, 2017 

    상세보기

24. Chang ZL, Hou AJ, Chen YY : Engineering primary T cells with chimeric？antigen receptors for rewired responses to soluble ligands. Nat Protoc？15 : 1507-1524, 2020 

    상세보기

25. Chmielewski M, Abken H : TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther 15 : 1145-1154, 

    상세보기

26. Cho BK, Rao VP, Ge Q, Eisen HN, Chen J : Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells.？J Exp Med 192 : 549-556, 2000 

    상세보기

27. Cho DY, Yang WK, Lee HC, Hsu DM, Lin HL, Lin SZ, et al. : Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial. World Neurosurg 77 : 736-744, 2012 

    상세보기

28. Choi BD, Yu X, Castano AP, Bouffard AA, Schmidts A, Larson RC, et al. :？CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol 37 : 1049-1058, 2019 

    상세보기

29. Choi BD, Yu X, Castano AP, Darr H, Henderson DB, Bouffard AA, et al. :？CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII？CAR T cells in a preclinical model of human glioblastoma. J Immunother Cancer 7 : 304, 2019 

    상세보기

30. Chow KK, Naik S, Kakarla S, Brawley VS, Shaffer DR, Yi Z, et al. : T cells？redirected to EphA2 for the immunotherapy of glioblastoma. Mol Ther？21 : 629-637, 2013 

    상세보기

31. Chung DS, Shin HJ, Hong YK : A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy. J Immunol Res 2014 :？326545, 2014 

    상세보기

32. Cinatl J, Scholz M, Kotchetkov R, Vogel JU, Doerr HW : Molecular？mechanisms of the modulatory effects of HCMV infection in tumor cell？biology. Trends Mol Med 10 : 19-23, 2004 

33. Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, et al. :？Human cytomegalovirus infection and expression in human malignant？glioma. Cancer Res 62 : 3347-3350, 2002 

34. Collins M, Ling V, Carreno BM : The B7 family of immune-regulatory？ligands. Genome Biol 6 : 223, 2005 

    상세보기

35. Crough T, Beagley L, Smith C, Jones L, Walker DG, Khanna R : Ex vivo？functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme. Immunol Cell？Biol 90 : 872-880, 2012 

    상세보기

36. Cui J, Wang H, Medina R, Zhang Q, Xu C, Indig IH, et al. : Inhibition of？PP2A with LB-100 enhances efficacy of CAR-T cell therapy against glioblastoma. Cancers (Basel) 12 : 139, 2020 

    상세보기

37. Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF : Type I？IFNs provide a third signal to CD8 T cells to stimulate clonal expansion？and differentiation. J Immunol 174 : 4465-4469, 2005 

38. Dardevet L, Rani D, Aziz TA, Bazin I, Sabatier JM, Fadl M, et al. : Chlorotoxin: a helpful natural scorpion peptide to diagnose glioma and fight？tumor invasion. Toxins (Basel) 7 : 1079-1101, 

    상세보기

39. DeBin JA, Maggio JE, Strichartz GR : Purification and characterization of？chlorotoxin, a chloride channel ligand from the venom of the scorpion.？Am J physiol 264(2 Pt 1) : C361-C369, 1993 

40. Debinski W, Gibo DM, Hulet SW, Connor JR, Gillespie GY : Receptor for？interleukin 13 is a marker and therapeutic target for human high-grade？gliomas. Clin Cancer Res 5 : 985-990, 1999 

41. Demaria S, Formenti SC : Sensors of ionizing radiation effects on the immunological microenvironment of cancer. Int J Radiat Biol 83 : 819-825, 2007 

    상세보기

42. DeSelm C, Palomba ML, Yahalom J, Hamieh M, Eyquem J, Rajasekhar？VK, et al. : Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape. Mol Ther 26 : 2542-2552, 2018 

    상세보기

43. Deshane J, Garner CC, Sontheimer H : Chlorotoxin inhibits glioma cell？invasion via matrix metalloproteinase-2. J Biol Chem 278 : 4135-4144,？2003 

    상세보기

44. Ding Z, Li Q, Zhang R, Xie L, Shu Y, Gao S, et al. : Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer. Signal？Transduct Target Ther 6 : 26, 2021 

45. Dobrzanski P, Hunter K, Jones-Bolin S, Chang H, Robinson C, Pritchard？S, et al. : Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res 64 : 910-919, 2004 

    상세보기

46. Doronin II, Vishnyakova PA, Kholodenko IV, Ponomarev ED, Ryazantsev？DY, Molotkovskaya IM, et al. : Ganglioside GD2 in reception and transduction of cell death signal in tumor cells. BMC Cancer 14 : 295, 2014 

    상세보기

47. Du H, Hirabayashi K, Ahn S, Kren NP, Montgomery SA, Wang X, et al. :？Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor T cells. Cancer Cell 35 : 221-237.e8, 2019 

    상세보기

48. Dustin ML, Shaw AS : Costimulation: building an immunological synapse. Science 283 : 649-650, 1999 

    상세보기

49. Eguizabal C, Zenarruzabeitia O, Monge J, Santos S, Vesga MA, Maruri？N, et al. : Natural killer cells for cancer immunotherapy: pluripotent stem？cells-derived NK cells as an immunotherapeutic perspective. Front Immunol 5 : 439, 2014 

50. Eiraku Y, Terunuma H, Yagi M, Deng X, Nicol AJ, Nieda M : Dendritic？cells cross-talk with tumour antigen-specific CD8+ T cells, Vγ9γδT cells？and Vα24NKT cells in patients with glioblastoma multiforme and in？healthy donors. Clin Exp Immunol 194 : 54-66, 2018 

51. Eshhar Z, Waks T, Gross G, Schindler DG : Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting？of antibody-binding domains and the gamma or zeta subunits of the？immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 90 :？720-724, 1993 

    상세보기

52. Fadul CE, Fisher JL, Gui J, Hampton TH, Cote AL, Ernstoff MS : Immune？modulation effects of concomitant temozolomide and radiation therapy？on peripheral blood mononuclear cells in patients with glioblastoma？multiforme. Neuro Oncol 13 : 393-400, 2011 

53. Fan H, Yi W, Wang C, Wang J : The clinicopathological significance and？prognostic value of EMMPRIN overexpression in cancers: evidence from？39 cohort studies. Oncotarget 8 : 82643-82660, 2017 

    상세보기

54. Fecci PE, Sampson JH : The current state of immunotherapy for gliomas:？an eye toward the future. J Neurosurg 131 : 657-666, 2019 

55. Fluh C, Chitadze G, Adamski V, Hattermann K, Synowitz M, Kabelitz D,？et al : NKG2D ligands in glioma stem-like cells: expression in situ and in？vitro. Histochem Cell Biol 149 : 219-233, 2018 

56. Formenti SC, Demaria S : Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 105 : 256-265, 2013 

    상세보기

57. Fujii R, Jochems C, Tritsch SR, Wong HC, Schlom J, Hodge JW : An IL-15 superagonist/IL-15rα fusion complex protects and rescues NK cell-cytotoxic function from TGF-β1-mediated immunosuppression. Cancer？Immunol Immunother 67 : 675-689, 2018 

58. Gargett T, Ebert LM, Truong NTH, Kollis PM, Sedivakova K, Yu W, et al. :？GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are？an effective and clinically feasible therapy for glioblastoma. J Immunother Cancer 10 : e005187, 2022 

    상세보기

59. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, et al. : A human memory T cell subset with stem cell-like properties. Nat Med 17 :？1290-1297, 2011 

    상세보기

60. Geller MA, Miller JS : Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy 3 : 1445-1459, 2011 

    상세보기

61. Genssler S, Burger MC, Zhang C, Oelsner S, Mildenberger I, Wagner M,？et al. : Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen？expression and enhances antitumor activity and survival. Oncoimmunology 5 : e1119354, 2016 

62. Gilfillan S, Ho EL, Cella M, Yokoyama WM, Colonna M : NKG2D recruits？two distinct adapters to trigger NK cell activation and costimulation.？Nat Immunol 3 : 1150-1155, 2002 

    상세보기

63. Giordano-Attianese G, Gainza P, Gray-Gaillard E, Cribioli E, Shui S, Kim？S, et al. : A computationally designed chimeric antigen receptor provides？a small-molecule safety switch for T-cell therapy. Nat Biotechnol 38 :？426-432, 2020 

    상세보기

64. Goff SL, Morgan RA, Yang JC, Sherry RM, Robbins PF, Restifo NP, et al. :？Pilot trial of adoptive transfer of chimeric antigen receptor-transduced T？cells targeting EGFRvIII in patients with glioblastoma. J Immunother？42 : 126-135, 2019 

    상세보기

65. Golinelli G, Grisendi G, Prapa M, Bestagno M, Spano C, Rossignoli F, et？al. : Targeting GD2-positive glioblastoma by chimeric antigen receptor？empowered mesenchymal progenitors. Cancer Gene Ther 27 : 558-570, 2020 

    상세보기

66. Grass GD, Toole BP : How, with whom and when: an overview of？CD147-mediated regulatory networks influencing matrix metalloproteinase activity. Biosci Rep 36 : e00283, 

    상세보기

67. Grimm EA, Robb RJ, Roth JA, Neckers LM, Lachman LB, Wilson DJ, et？al. : Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2？is sufficient for direct activation of peripheral blood lymphocytes into？lymphokine-activated killer cells. J Exp Med 158 : 1356-1361, 1983 

    상세보기

68. Han J, Chu J, Keung Chan W, Zhang J, Wang Y, Cohen JB, et al. : CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance？killing of glioblastoma and patient-derived glioblastoma stem cells. Sci？Rep 5 : 11483, 

    상세보기

69. Haspels HN, Rahman MA, Joseph JV, Gras Navarro A, Chekenya M :？Glioblastoma stem-like cells are more susceptible than differentiated？cells to natural killer cell lysis mediated through killer immunoglobulin-like receptors-human leukocyte antigen ligand mismatch and activation？receptor-ligand interactions. Front Immunol 9 : 1345, 2018 

70. Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore EJ,？et al. : Improved long term survival after intracavitary interleukin-2 and？lymphokine-activated killer cells for adults with recurrent malignant？glioma. Cancer 76 : 840-852, 1995 

71. Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, et al. :？Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen？escape. J Clin Invest 126 : 3036-3052, 2016 

72. Hermanson DL, Kaufman DS : Utilizing chimeric antigen receptors to？direct natural killer cell activity. Front Immunol 6 : 195, 

73. Hombach AA, Chmielewski M, Rappl G, Abken H : Adoptive immunotherapy with redirected T cells produces CCR7- cells that are trapped in？the periphery and benefit from combined CD28-OX40 costimulation.？Hum Gene Ther 24 : 259-269, 2013 

    상세보기

74. Huang J, Zheng M, Zhang Z, Tang X, Chen Y, Peng A, et al. : Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma. Cancer Immunol Immunother 70 : 2453-2465, 2021 

    상세보기

75. Huang RS, Shih HA, Lai MC, Chang YJ, Lin S : Enhanced NK-92 cytotoxicity by CRISPR genome engineering using Cas9 ribonucleoproteins.？Front Immunol 11 : 1008, 2020 

76. Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC, et al. :？Defining CD8+ T cells that provide the proliferative burst after PD-1？therapy. Nature 537 : 417-421, 2016 

77. Ishikawa E, Tsuboi K, Saijo K, Harada H, Takano S, Nose T, et al. : Autologous natural killer cell therapy for human recurrent malignant glioma.？Anticancer Res 24 : 1861-1871, 2004 

    상세보기

78. Jackaman C, Majewski D, Fox SA, Nowak AK, Nelson DJ : Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8(+) T？cells in vivo. Cancer Immunol Immunother 61 : 2343-2356, 2012 

    상세보기

79. Jin L, Ge H, Long Y, Yang C, Chang YE, Mu L, et al. : CD70, a novel target of CAR T-cell therapy for gliomas. Neuro Oncol 20 : 55-65, 2018 

80. Jin L, Tao H, Karachi A, Long Y, Hou AY, Na M, et al. : CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in？solid tumors. Nat Commun 10 : 4016, 2019 

    상세보기

81. Johnsen JI, Baryawno N, Soderberg-Naucler C : Is human cytomegalovirus a target in cancer therapy? Oncotarget 2 : 1329-1338, 2011 

    상세보기

82. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS,？et al. : Gene therapy with human and mouse T-cell receptors mediates？cancer regression and targets normal tissues expressing cognate antigen. Blood 114 : 535-546, 2009 

    상세보기

83. Juillerat A, Tkach D, Busser BW, Temburni S, Valton J, Duclert A, et al. :？Modulation of chimeric antigen receptor surface expression by a small？molecule switch. BMC Biotechnol 19 : 44, 2019 

    상세보기

84. Kagoya Y, Tanaka S, Guo T, Anczurowski M, Wang CH, Saso K, et al. : A？novel chimeric antigen receptor containing a JAK-STAT signaling domain？mediates superior antitumor effects. Nat Med 24 : 352-359, 2018 

    상세보기

85. Karagiannis P, Kim SI : iPSC-derived natural killer cells for cancer immunotherapy. Mol Cells 44 : 541-548, 2021 

    원문보기 상세보기

86. Kaufman HL, Kohlhapp FJ, Zloza A : Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov 14 : 642-662, 

87. Kawakami M, Kawakami K, Takahashi S, Abe M, Puri RK : Analysis of？interleukin-13 receptor alpha2 expression in human pediatric brain tumors. Cancer 101 : 1036-1042, 2004 

88. Kawalekar OU, O'Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey？AD Jr, et al. : Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells.？Immunity 44 : 380-390, 2016 

    상세보기

89. Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, et al. :？Neoantigen vaccine generates intratumoral T cell responses in phase Ib？glioblastoma trial. Nature 565 : 234-239, 2019 

90. Kim CG, Kim KH, Pyo KH, Xin CF, Hong MH, Ahn BC, et al. : Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. Ann Oncol 30 : 1104-1113, 2019 

    상세보기

91. Kim N, Kim HS : Targeting checkpoint receptors and molecules for？therapeutic modulation of natural killer cells. Front Immunol 9 : 2041,？2018 

92. Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L,？Theoret MR, et al. : IL-15 enhances the in vivo antitumor activity of？tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A 101 : 1969-1974, 2004 

    상세보기

93. Klingemann H, Boissel L, Toneguzzo F : Natural killer cells for immunotherapy - advantages of the NK-92 cell line over blood NK cells. Front？Immunol 7 : 91, 2016 

94. Klinger M, Benjamin J, Kischel R, Stienen S, Zugmaier G : Harnessing T？cells to fight cancer with BiTE® antibody constructs--past developments？and future directions. Immunol Rev 270 : 193-208, 2016 

95. Knorr DA, Ni Z, Hermanson D, Hexum MK, Bendzick L, Cooper LJ, et al. :？Clinical-scale derivation of natural killer cells from human pluripotent？stem cells for cancer therapy. Stem Cells Transl Med 2 : 274-283,？2013 

    상세보기

96. Koike N, Pilon-Thomas S, Mule JJ : Nonmyeloablative chemotherapy？followed by T-cell adoptive transfer and dendritic cell-based vaccination？results in rejection of established melanoma. J Immunother 31 : 402-412, 2008 

    상세보기

97. Koka V, Potti A, Forseen SE, Pervez H, Fraiman GN, Koch M, et al. : Role？of Her-2/neu overexpression and clinical determinants of early mortality？in glioblastoma multiforme. Am J Clin Oncol 26 : 332-335, 2003 

    상세보기

98. Kowolik CM, Topp MS, Gonzalez S, Pfeiffer T, Olivares S, Gonzalez N,？et al. : CD28 costimulation provided through a CD19-specific chimeric？antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res 66 : 10995-11004, 2006 

    상세보기

99. Krenciute G, Prinzing BL, Yi Z, Wu MF, Liu H, Dotti G, et al. : Transgenic？expression of IL15 improves antiglioma activity of IL13Rα2-CAR T cells？but results in antigen loss variants. Cancer Immunol Res 5 : 571-581,？2017 

100. Kumar S : Natural killer cell cytotoxicity and its regulation by inhibitory？receptors. Immunology 154 : 383-393, 2018 

101. Kwon HJ, Kim N, Kim HS : Molecular checkpoints controlling natural？killer cell activation and their modulation for cancer immunotherapy.？Exp Mol Med 49 : e311, 2017 

     상세보기

102. Landras A, Reger de Moura C, Jouenne F, Lebbe C, Menashi S, Mourah？S : CD147 is a promising target of tumor progression and a prognostic？biomarker. Cancers (Basel) 11 : 1803, 2019 

103. Lanier LL : Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 9 : 495-502, 2008 

     상세보기

104. Lazarova M, Steinle A : Impairment of NKG2D-mediated tumor immunity？by TGF-β. Front Immunol 10 : 2689, 2019 

105. Leibson PJ : Signal transduction during natural killer cell activation: inside the mind of a killer. Immunity 6 : 655-661, 1997 

     상세보기

106. Li G, Zhang Z, Cai L, Tang X, Huang J, Yu L, et al. : Fn14-targeted BiTE？and CAR-T cells demonstrate potent preclinical activity against glioblastoma. Oncoimmunology 10 : 1983306, 2021 

     상세보기

107. Li H, Ding J, Lu M, Liu H, Miao Y, Li L, et al. : CAIX-specific CAR-T cells？and sunitinib show synergistic effects against metastatic renal cancer？models. J Immunother 43 : 16-28, 2020 

     상세보기

108. Li L, Goedegebuure P, Mardis ER, Ellis MJ, Zhang X, Herndon JM, et al. :？Cancer genome sequencing and its implications for personalized cancer？vaccines. Cancers (Basel) 3 : 4191-4211, 2011 

109. Li S, Siriwon N, Zhang X, Yang S, Jin T, He F, et al. : Enhanced cancer？immunotherapy by chimeric antigen receptor-modified T cells engineered？to secrete checkpoint inhibitors. Clin Cancer Res 23 : 6982-6992,？2017 

     상세보기

110. Li T, Zhang Q, Jiang Y, Yu J, Hu Y, Mou T, et al. : Gastric cancer cells inhibit natural killer cell proliferation and induce apoptosis via prostaglandin E2. Oncoimmunology 5 : e1069936, 2016 

111. Li Y, Hermanson DL, Moriarity BS, Kaufman DS : Human iPSC-derived？natural killer cells engineered with chimeric antigen receptors enhance？anti-tumor activity. Cell Stem Cell 23 : 181-192.e5, 2018 

     상세보기

112. Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, et al. :？First results on survival from a large phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl？Med 16 : 142, 2018 

     상세보기

113. Lim J, Park Y, Ahn JW, Sim J, Kang SJ, Hwang S, et al. : Autologous？adoptive immune-cell therapy elicited a durable response with enhanced？immune reaction signatures in patients with recurrent glioblastoma: an？open label, phase I/IIa trial. PLoS One 16 : e0247293, 2021 

     상세보기

114. Lin Q, Ba T, Ho J, Chen D, Cheng Y, Wang L, et al. : First-in-human trial？of EphA2-redirected CAR T-cells in patients with recurrent glioblastoma:？a preliminary report of three cases at the starting dose. Front Oncol？11 : 694941, 2021 

     상세보기

115. Lin Y, Okada H : Cellular immunotherapy for malignant gliomas. Expert？Opin Biol Ther 16 : 1265-1275, 2016 

     상세보기

116. Liu X, Ranganathan R, Jiang S, Fang C, Sun J, Kim S, et al. : A chimeric？switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors. Cancer Res 76 : 1578-1590,？2016 

     상세보기

117. Lohr J, Ratliff T, Huppertz A, Ge Y, Dictus C, Ahmadi R, et al. : Effector？T-cell infiltration positively impacts survival of glioblastoma patients and？is impaired by tumor-derived TGF-β. Clin Cancer Res 17 : 4296-4308,？2011 

118. Long EO : Negative signaling by inhibitory receptors: the NK cell paradigm. Immunol Rev 224 : 70-84, 2008 

     상세보기

119. Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S : Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol 31 : 227-258, 2013 

     상세보기

120. Longee DC, Wikstrand CJ, Mansson JE, He X, Fuller GN, Bigner SH, et al. :？Disialoganglioside GD2 in human neuroectodermal tumor cell lines and？gliomas. Acta Neuropathol 82 : 45-54, 1991 

121. Lyons SA, O'Neal J, Sontheimer H : Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin.？Glia 39 : 162-173, 2002 

     상세보기

122. Ma R, Lu T, Li Z, Teng KY, Mansour AG, Yu M, et al. : An oncolytic virus？expressing IL15/IL15Rα combined with off-the-shelf EGFR-CAR NK cells？targets glioblastoma. Cancer Res 81 : 3635-3648, 2021 

123. Ma X, Holt D, Kundu N, Reader J, Goloubeva O, Take Y, et al. : A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from？PGE2-mediated immunosuppression and inhibits breast cancer metastasis. Oncoimmunology 2 : e22647, 2013 

     상세보기

124. Majzner RG, Ramakrishna S, Yeom KW, Patel S, Chinnasamy H, Schultz？LM, et al. : GD2-CAR T cell therapy for H3K27M-mutated diffuse midline？gliomas. Nature 603 : 934-941, 2011 

125. Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, et？al. : CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors.？Clin Cancer Res 25 : 2560-2574, 2019 

     상세보기

126. Mamelak AN, Rosenfeld S, Bucholz R, Raubitschek A, Nabors LB,？Fiveash JB, et al. : Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. J？Clin Oncol 24 : 3644-3650, 2006 

127. Manley TJ, Luy L, Jones T, Boeckh M, Mutimer H, Riddell SR : Immune？evasion proteins of human cytomegalovirus do not prevent a diverse？CD8+ cytotoxic T-cell response in natural infection. Blood 104 : 1075-1082, 2004 

     상세보기

128. Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. :？TGFβ attenuates tumour response to PD-L1 blockade by contributing to？exclusion of T cells. Nature 554 : 544-548, 2018 

129. McFerrin MB, Sontheimer H : A role for ion channels in glioma cell invasion. Neuron Glia Biol 2 : 39-49, 2006 

130. McNerney ME, Lee KM, Kumar V : 2B4 (CD244) is a non-MHC binding？receptor with multiple functions on natural killer cells and CD8+ T cells.？Mol Immunol 42 : 489-494, 2005 

     상세보기

131. Meister H, Look T, Roth P, Pascolo S, Sahin U, Lee S, et al. : Multifunctional mRNA-based CAR T cells display promising antitumor activity？against glioblastoma. Clin Cancer Res 28 : 4747-4756, 2022 

     상세보기

132. Miao H, Li DQ, Mukherjee A, Guo H, Petty A, Cutter J, et al. : EphA2？mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with？Akt. Cancer Cell 16 : 9-20, 2009 

     상세보기

133. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH,？Fautsch SK, et al. : Successful adoptive transfer and in vivo expansion？of human haploidentical NK cells in patients with cancer. Blood 105 :？3051-3057, 2005 

     상세보기

134. Mineo JF, Bordron A, Baroncini M, Maurage CA, Ramirez C, Siminski？RM, et al. : Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma. J Neurooncol？85 : 281-287, 2007 

     상세보기

135. Modak S, Kramer K, Gultekin SH, Guo HF, Cheung NK : Monoclonal？antibody 8H9 targets a novel cell surface antigen expressed by a wide？spectrum of human solid tumors. Cancer Res 61 : 4048-4054, 2001 

     상세보기

136. Mohme M, Schliffke S, Maire CL, Runger A, Glau L, Mende KC, et al. :？Immunophenotyping of newly diagnosed and recurrent glioblastoma？defines distinct immune exhaustion profiles in peripheral and tumor-infiltrating lymphocytes. Clin Cancer Res 24 : 4187-4200, 2018 

     상세보기

137. Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z,？et al. : Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 36 : 133-151, 2013 

     상세보기

138. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry？RM, et al. : Cancer regression in patients after transfer of genetically？engineered lymphocytes. Science 314 : 126-129, 2006 

     상세보기

139. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg？SA : Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing？ERBB2. Mol Ther 18 : 843-851, 2010 

     상세보기

140. Mount CW, Majzner RG, Sundaresh S, Arnold EP, Kadapakkam M, Haile S,？et al. : Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+diffuse midline gliomas. Nat Med 24 : 572-579, 2018 

     상세보기

141. Muller N, Michen S, Tietze S, Topfer K, Schulte A, Lamszus K, et al. :？Engineering NK cells modified with an EGFRvIII-specific chimeric antigen？receptor to overexpress CXCR4 improves immunotherapy of CXCL12/SDF-1α-secreting glioblastoma. J Immunother 38 : 197-210, 

142. Murakami T, Nakazawa T, Natsume A, Nishimura F, Nakamura M, Matsuda R, et al. : Novel human NK cell line carrying CAR targeting EGFRvIII？induces antitumor effects in glioblastoma cells. Anticancer Res 38 :？5049-5056, 2018 

     상세보기

143. Nagorsen D, Baeuerle PA : Immunomodulatory therapy of cancer with T？cell-engaging BiTE antibody blinatumomab. Exp Cell Res 317 : 1255-1260, 2011 

     상세보기

144. Nair S, Wang JB, Tsao ST, Liu Y, Zhu W, Slayton WB, et al. : Functional？improvement of chimeric antigen receptor through intrinsic interleukin-15Rα signaling. Curr Gene Ther 19 : 40-53, 2019 

145. Nausch N, Cerwenka A : NKG2D ligands in tumor immunity. Oncogene？27 : 5944-5958, 2008 

     상세보기

146. Nejo T, Yamamichi A, Almeida ND, Goretsky YE, Okada H : Tumor antigens in glioma. Semin Immunol 47 : 101385, 2020 

     상세보기

147. O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, et al. : A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in？patients with recurrent glioblastoma. Sci Transl Med 9 : eaaa0984,？2017 

     상세보기

148. Odorizzi PM, Pauken KE, Paley MA, Sharpe A, Wherry EJ : Genetic？absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells. J Exp Med 212 : 1125-1137, 

     상세보기

149. Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL, Pasquale EB :？The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 19 : 6043-6052, 2000 

     상세보기

150. O'Rourke D, Desai A, Morrissette J, Martinez-Lage M, Nasrallah M,？Brem S, et al. : IMCT-15 PILOT study of T cells redirected to EGFRvIII with？a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma.？Neuro Oncol 17(suppl_5) : v110-v111, 

151. Ott PA, Govindan R, Naing A, Friedlander TW, Margolin K, Lin JJ, et al. :？A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces？broad de novo anti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer. Ann Oncol 29 : viii400, 2018 

     상세보기

152. Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. : An immunogenic personal neoantigen vaccine for patients with melanoma.？Nature 547 : 217-221, 2017 

153. Park A, Lee Y, Kim MS, Kang YJ, Park YJ, Jung H, et al. : Prostaglandin E2 secreted by thyroid cancer cells contributes to immune escape？through the suppression of natural killer (NK) cell cytotoxicity and NK？cell differentiation. Front Immunol 9 : 1859, 2018 

154. Park J, Kwon M, Kim KH, Kim TS, Hong SH, Kim CG, et al. : Immune？checkpoint inhibitor-induced reinvigoration of tumor-infiltrating CD8+？T cells is determined by their differentiation status in glioblastoma. Clin？Cancer Res 25 : 2549-2559, 2019 

155. Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman？SA, et al. : T cells targeting carcinoembryonic antigen can mediate？regression of metastatic colorectal cancer but induce severe transient？colitis. Mol Ther 19 : 620-626, 2011 

156. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et？al. : Single-cell RNA-seq highlights intratumoral heterogeneity in primary？glioblastoma. Science 344 : 1396-1401, 2014 

     상세보기

157. Paulos CM, Kaiser A, Wrzesinski C, Hinrichs CS, Cassard L, Boni A, et al. :？Toll-like receptors in tumor immunotherapy. Clin Cancer Res 13(18 Pt？1) : 5280-5289, 2007 

158. Pfefferle A, Huntington ND : You have got a fast CAR: chimeric antigen？receptor NK cells in cancer therapy. Cancers (Basel) 12 : 706, 2020 

     상세보기

159. Phillips JH, Lanier LL : Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells？and T lymphocytes to cytolysis. J Exp Med 164 : 814-825, 1986 

     상세보기

160. Picarda E, Ohaegbulam KC, Zang X : Molecular pathways: targeting B7-H3 (CD276) for human cancer immunotherapy. Clin Cancer Res 22 :？3425-3431, 2016 

     상세보기

161. Pickup M, Novitskiy S, Moses HL : The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer 13 : 788-799, 2013 

162. Plautz GE, Barnett GH, Miller DW, Cohen BH, Prayson RA, Krauss JC,？et al. : Systemic T cell adoptive immunotherapy of malignant gliomas. J？Neurosurg 89 : 42-51, 1998 

163. Plautz GE, Miller DW, Barnett GH, Stevens GH, Maffett S, Kim J, et al. : T？cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer？Res 6 : 2209-2218, 2000 

     상세보기

164. Poirot L, Philip B, Schiffer-Mannioui C, Le Clerre D, Chion-Sotinel I, Derniame S, et al. : Multiplex genome-edited T-cell manufacturing platform？for "Off-the-Shelf" adoptive T-cell immunotherapies. Cancer Res 75 :？3853-3864, 

165. Powell AB, Yadavilli S, Saunders D, Van Pelt S, Chorvinsky E, Burga RA,？et al. : Medulloblastoma rendered susceptible to NK-cell attack by TGFβ？neutralization. J Transl Med 17 : 321, 2019 

166. Prager I, Watzl C : Mechanisms of natural killer cell-mediated cellular？cytotoxicity. J Leukoc Biol 105 : 1319-1329, 2019 

     상세보기

167. Prapa M, Chiavelli C, Golinelli G, Grisendi G, Bestagno M, Di Tinco R, et？al. : GD2 CAR T cells against human glioblastoma. NPJ Precis Oncol 5 :？93, 2021 

168. Provasi E, Genovese P, Lombardo A, Magnani Z, Liu PQ, Reik A, et al. :？Editing T cell specificity towards leukemia by zinc finger nucleases and？lentiviral gene transfer. Nat Med 18 : 807-815, 2012 

     상세보기

169. Rafiq S, Hackett CS, Brentjens RJ : Engineering strategies to overcome？the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol 17 :？147-167, 2020 

     상세보기

170. Rajesh E, Sankari LS, Malathi L, Krupaa JR : Naturally occurring products？in cancer therapy. J Pharm Bioallied Sci 7(Suppl 1) : S181-S183,？2015 

171. Ranson T, Vosshenrich CA, Corcuff E, Richard O, Muller W, Di Santo JP :？IL-15 is an essential mediator of peripheral NK-cell homeostasis. Blood？101 : 4887-4893, 2003 

     상세보기

172. Reap EA, Suryadevara CM, Batich KA, Sanchez-Perez L, Archer GE,？Schmittling RJ, et al. : Dendritic cells enhance polyfunctionality of adoptively transferred T cells that target cytomegalovirus in glioblastoma.？Cancer Res 78 : 256-264, 2018 

     상세보기

173. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, et al. : Radiation modulates the peptide repertoire, enhances？MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 203 : 1259-1271, 2006 

     상세보기

174. Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y : Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin？Cancer Res 23 : 2255-2266, 2017 

175. Rezvani K, Rouce RH : The application of natural killer cell immunotherapy for the treatment of cancer. Front Immunol 6 : 578, 

176. Riccione K, Suryadevara CM, Snyder D, Cui X, Sampson JH, Sanchez-Perez L : Generation of CAR T cells for adoptive therapy in the context？of glioblastoma standard of care. J Vis Exp 96 : 52397, 

177. Romani M, Pistillo MP, Carosio R, Morabito A, Banelli B : Immune checkpoints and innovative therapies in glioblastoma. Front Oncol 8 : 464,？2018 

     상세보기

178. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et？al. : Effectiveness of donor natural killer cell alloreactivity in mismatched？hematopoietic transplants. Science 295 : 2097-2100, 2002 

     상세보기

179. Sahebjam S, Sharabi A, Lim M, Kesarwani P, Chinnaiyan P : Immunotherapy and radiation in glioblastoma. J Neurooncol 134 : 531-539,？2017 

     상세보기

180. Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Lower M, et al. :？Personalized RNA mutanome vaccines mobilize poly-specific therapeutic？immunity against cancer. Nature 547 : 222-226, 2017 

181. Salem ML, Cole DJ : Dendritic cell recovery post-lymphodepletion: a？potential mechanism for anti-cancer adoptive T cell therapy and vaccination. Cancer Immunol Immunother 59 : 341-353, 2010 

     상세보기

182. Sampson JH, Choi BD, Sanchez-Perez L, Suryadevara CM, Snyder DJ,？Flores CT, et al. : EGFRvIII mCAR-modified T-cell therapy cures mice with？established intracerebral glioma and generates host immunity against？tumor-antigen loss. Clin Cancer Res 20 : 972-984, 2014 

     상세보기

183. Sanchez CE, Dowlati EP, Geiger AE, Chaudhry K, Tovar MA, Bollard CM,？et al. : NK cell adoptive immunotherapy of cancer: evaluating recognition strategies and overcoming limitations. Transplant Cell Ther 27 :？21-35, 2021 

184. Sarivalasis A, Boudousquie C, Balint K, Stevenson BJ, Gannon PO, Iancu？EM, et al. : A phase I/II trial comparing autologous dendritic cell vaccine？pulsed either with personalized peptides (PEP-DC) or with tumor lysate？(OC-DC) in patients with advanced high-grade ovarian serous carcinoma. J Transl Med 17 : 391, 2019 

185. Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN,？et al. : Is the blood-brain barrier really disrupted in all glioblastomas? A？critical assessment of existing clinical data. Neuro Oncol 20 : 184-191,？2018 

186. Schiltz PM, Beutel LD, Nayak SK, Dillman RO : Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive？immunotherapy of cancer. J Immunother 20 : 377-386, 1997 

     상세보기

187. Schuessler A, Smith C, Beagley L, Boyle GM, Rehan S, Matthews K, et？al. : Autologous T-cell therapy for cytomegalovirus as a consolidative？treatment for recurrent glioblastoma. Cancer Res 74 : 3466-3476,？2014 

     상세보기

188. Seaman S, Zhu Z, Saha S, Zhang XM, Yang MY, Hilton MB, et al. :？Eradication of tumors through simultaneous ablation of CD276/B7-H3-positive tumor cells and tumor vasculature. Cancer Cell 31 : 501-515.？e8, 2017 

     상세보기

189. Shaim H, Shanley M, Basar R, Daher M, Gumin J, Zamler DB, et al. :？Targeting the αv integrin/TGF-β axis improves natural killer cell function？against glioblastoma stem cells. J Clin Invest 131 : e142116, 2021 

190. Shen SH, Woroniecka K, Barbour AB, Fecci PE, Sanchez-Perez L, Sampson JH : CAR T cells and checkpoint inhibition for the treatment of glioblastoma. Expert Opin Biol Ther 20 : 579-591, 2020 

     상세보기

191. Shimada A : Hematological malignancies and molecular targeting therapy. Eur J Pharmacol 862 : 172641, 2019 

     상세보기

192. Shin MH, Kim J, Lim SA, Kim J, Kim SJ, Lee KM : NK cell-based immunotherapies in cancer. Immune Netw 20 : e14, 2020 

193. Siegler EL, Zhu Y, Wang P, Yang L : Off-the-shelf CAR-NK cells for cancer？immunotherapy. Cell Stem Cell 23 : 160-161, 2018 

     상세보기

194. Song Y, Liu Q, Zuo T, Wei G, Jiao S : Combined antitumor effects of anti-EGFR variant III CAR-T cell therapy and PD-1 checkpoint blockade on？glioblastoma in mouse model. Cell Immunol 352 : 104112, 2020 

     상세보기

195. Soroceanu L, Gillespie Y, Khazaeli MB, Sontheimer H : Use of chlorotoxin？for targeting of primary brain tumors. Cancer Res 58 : 4871-4879,？1998 

     상세보기

196. Speiser DE, Miranda R, Zakarian A, Bachmann MF, McKall-Faienza K,？Odermatt B, et al. : Self antigens expressed by solid tumors do not？efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med 186 : 645-653, 1997 

     상세보기

197. Steeghs N, Nortier JW, Gelderblom H : Small molecule tyrosine kinase？inhibitors in the treatment of solid tumors: an update of recent developments. Ann Surg Oncol 14 : 942-953, 2007 

     상세보기

198. Suarez ER, Chang de K, Sun J, Sui J, Freeman GJ, Signoretti S, et al. :？Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more？effectively regress renal cell carcinoma in a humanized mouse model.？Oncotarget 7 : 34341-34355, 2016 

     상세보기

199. Suck G, Odendahl M, Nowakowska P, Seidl C, Wels WS, Klingemann？HG, et al. : NK-92: an 'off-the-shelf therapeutic' for adoptive natural？killer cell-based cancer immunotherapy. Cancer Immunol Immunother 65 : 485-492, 2016 

     상세보기

200. Suryadevara CM, Gedeon PC, Sanchez-Perez L, Verla T, Alvarez-Breckenridge C, Choi BD, et al. : Are BiTEs the "missing link" in cancer？therapy? Oncoimmunology 4 : e1008339, 

     상세보기

201. Tatenhorst L, Rescher U, Gerke V, Paulus W : Knockdown of annexin 2？decreases migration of human glioma cells in vitro. Neuropathol Appl？Neurobiol 32 : 271-277, 2006 

     상세보기

202. Tonn T, Becker S, Esser R, Schwabe D, Seifried E : Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J？Hematother Stem Cell Res 10 : 535-544, 2001 

203. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott？DF, et al. : Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer？treated with nivolumab. JAMA Oncol 5 : 1411-1420, 2019 

     상세보기

204. Torikai H, Reik A, Liu PQ, Zhou Y, Zhang L, Maiti S, et al. : A foundation？for universal T-cell based immunotherapy: T cells engineered to express？a CD19-specific chimeric-antigen-receptor and eliminate expression of？endogenous TCR. Blood 119 : 5697-5705, 2012 

     상세보기

205. Touat M, Idbaih A, Sanson M, Ligon KL : Glioblastoma targeted therapy:？updated approaches from recent biological insights. Ann Oncol 28 :？1457-1472, 2017 

     상세보기

206. Tran NL, McDonough WS, Savitch BA, Fortin SP, Winkles JA, Symons？M, et al. : Increased fibroblast growth factor-inducible 14 expression？levels promote glioma cell invasion via Rac1 and nuclear factor-kappaB？and correlate with poor patient outcome. Cancer Res 66 : 9535-9542,？2006 

207. Trotta R, Dal Col J, Yu J, Ciarlariello D, Thomas B, Zhang X, et al. : TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production？and antibody-dependent cellular cytotoxicity in human NK cells. J Immunol 181 : 3784-3792, 2008 

208. Upreti D, Bakhshinyan D, Bloemberg D, Vora P, Venugopal C, Singh SK :？Strategies to enhance the efficacy of T-cell therapy for central nervous？system tumors. Front Immunol 11 : 599253, 2020 

209. van Buuren MM, Calis JJ, Schumacher TN : High sensitivity of cancer？exome-based CD8 T cell neo-antigen identification. Oncoimmunology？3 : e28836, 2014 

     상세보기

210. Veiseh M, Gabikian P, Bahrami SB, Veiseh O, Zhang M, Hackman RC,？et al. : Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative？visualization of cancer foci. Cancer Res 67 : 6882-6888, 2007 

     상세보기

211. Verneris MR, Miller JS : the phenotypic and functional characteristics of？umbilical cord blood and peripheral blood natural killer cells. Br J Haematol 147 : 185-191, 2009 

     상세보기

212. Vigdorovich V, Ramagopal UA, Lazar-Molnar E, Sylvestre E, Lee JS, Hofmeyer KA, et al. : Structure and T cell inhibition properties of B7 family？member, B7-H3. Structure 21 : 707-717, 2013 

     상세보기

213. Voskoboinik I, Smyth MJ, Trapani JA : Perforin-mediated target-cell？death and immune homeostasis. Nat Rev Immunol 6 : 940-952,？2006 

     상세보기

214. Wallen H, Thompson JA, Reilly JZ, Rodmyre RM, Cao J, Yee C : Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma.？PLoS One 4 : e4749, 2009 

     상세보기

215. Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E : Natural-killer cells？and dendritic cells: "l'union fait la force". Blood 106 : 2252-2258, 2005 

     상세보기

216. Walzer T, Dalod M, Vivier E, Zitvogel L : Natural killer cell-dendritic cell？crosstalk in the initiation of immune responses. Expert Opin Biol Ther？5 Suppl 1 : S49-S59, 2005 

217. Wang D, Quan Y, Yan Q, Morales JE, Wetsel RA : Targeted disruption？of the β2-microglobulin gene minimizes the immunogenicity of human？embryonic stem cells. Stem Cells Transl Med 4 : 1234-1245, 

218. Wang D, Starr R, Chang WC, Aguilar B, Alizadeh D, Wright SL, et al. :？Chlorotoxin-directed CAR T cells for specific and effective targeting of？glioblastoma. Sci Transl Med 12 : eaaw2672, 2020 

     상세보기

219. Wang G, Zhang Z, Zhong K, Wang Z, Yang N, Tang X, et al. : CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy？and reprogram tumor microenvironment in glioblastoma. Mol Ther 31 :？134-153, 2023 

     상세보기

220. Wang J, Toregrosa-Allen S, Elzey BD, Utturkar S, Lanman NA, Bernal-Crespo V, et al. : Multispecific targeting of glioblastoma with tumor？microenvironment-responsive multifunctional engineered NK cells. Proc？Natl Acad Sci U S A 118 : e2107507118, 2021 

     상세보기

221. Wang LF, Fokas E, Bieker M, Rose F, Rexin P, Zhu Y, et al. : Increased？expression of EphA2 correlates with adverse outcome in primary and？recurrent glioblastoma multiforme patients. Oncol Rep 19 : 151-156,？2008 

222. Wang QM, Tang PM, Lian GY, Li C, Li J, Huang XR, et al. : Enhanced？cancer immunotherapy with Smad3-silenced NK-92 cells. Cancer Immunol Res 6 : 965-977, 2018 

223. Weathers SP, Penas-Prado M, Pei BL, Ling X, Kassab C, Banerjee P, et al. :？Glioblastoma-mediated immune dysfunction limits CMV-specific T cells？and therapeutic responses: results from a phase I/II trial. Clin Cancer？Res 26 : 3565-3577, 2020 

     상세보기

224. Wei J, Luo C, Wang Y, Guo Y, Dai H, Tong C, et al. : PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T？cells by inhibiting proliferation activity. J Immunother Cancer 7 : 209,？2019 

     상세보기

225. Weiss T, Schneider H, Silginer M, Steinle A, Pruschy M, Polic B, et al. :？NKG2D-dependent antitumor effects of chemotherapy and radiotherapy？against glioblastoma. Clin Cancer Res 24 : 882-895, 2018 

     상세보기

226. Weiss T, Weller M, Guckenberger M, Sentman CL, Roth P : NKG2Dbased CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma. Cancer Res 78 : 1031-1043, 2018 

     상세보기

227. Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, et al. :？Rindopepimut with temozolomide for patients with newly diagnosed,？EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind,？international phase 3 trial. Lancet Oncol 18 : 1373-1385, 2017 

     상세보기

228. Wen PY, Reardon DA, Armstrong TS, Phuphanich S, Aiken RD, Landolfi？JC, et al. : A randomized double-blind placebo-controlled phase II trial of？dendritic cell vaccine ICT-107 in newly diagnosed patients with glioblastoma. Clin Cancer Res 25 : 5799-5807, 2019 

     상세보기

229. Wherry EJ : T cell exhaustion. Nat Immunol 12 : 492-499, 2011 

     상세보기

230. Wherry EJ, Blattman JN, Murali-Krishna K, van der Most R, Ahmed R :？Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol？77 : 4911-4927, 2003 

     상세보기

231. Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD : Cell surface？localization and density of the tumor-associated variant of the epidermal？growth factor receptor, EGFRvIII. Cancer Res 57 : 4130-4140, 1997 

     상세보기

232. Woan KV, Kim H, Bjordahl R, Davis ZB, Gaidarova S, Goulding J, et al. :？Harnessing features of adaptive NK cells to generate iPSC-derived NK？cells for enhanced immunotherapy. Cell Stem Cell 28 : 2062-2075.e5,？2021 

     상세보기

233. Wolf E, Hofmeister R, Kufer P, Schlereth B, Baeuerle PA : BiTEs: bispecific antibody constructs with unique anti-tumor activity. Drug Discov？Today 10 : 1237-1244, 2005 

234. Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, Farber SH, et al. : T-cell exhaustion signatures vary with tumor type and are？severe in glioblastoma. Clin Cancer Res 24 : 4175-4186, 2018 

     상세보기

235. Wu X, Luo H, Shi B, Di S, Sun R, Su J, et al. : Combined antitumor effects？of sorafenib and GPC3-CAR T cells in mouse models of hepatocellular？carcinoma. Mol Ther 27 : 1483-1494, 2019 

     상세보기

236. Wykosky J, Gibo DM, Stanton C, Debinski W : EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res 3 :？541-551, 2005 

     상세보기

237. Xiong L, Edwards CK 3rd, Zhou L : The biological function and clinical？utilization of CD147 in human diseases: a review of the current scientific？literature. Int J Mol Sci 15 : 17411-17441, 2014 

238. Yang B, Liu H, Shi W, Wang Z, Sun S, Zhang G, et al. : Blocking transforming growth factor-β signaling pathway augments antitumor effect？of adoptive NK-92 cell therapy. Int Immunopharmacol 17 : 198-204,？2013 

239. Yang D, Sun B, Dai H, Li W, Shi L, Zhang P, et al. : T cells expressing？NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and？cancer stem cells. J Immunother Cancer 7 : 171, 2019 

     상세보기

240. Yang I, Han SJ, Sughrue ME, Tihan T, Parsa AT : Immune cell infiltrate？differences in pilocytic astrocytoma and glioblastoma: evidence of？distinct immunological microenvironments that reflect tumor biology. J？Neurosurg 115 : 505-511, 2011 

241. Yang M, Yuan Y, Zhang H, Yan M, Wang S, Feng F, et al. : Prognostic significance of CD147 in patients with glioblastoma. J Neurooncol 115 :？19-26, 2013 

     상세보기

242. Yang W, Lee KW, Srivastava RM, Kuo F, Krishna C, Chowell D, et al. :？Immunogenic neoantigens derived from gene fusions stimulate T cell？responses. Nat Med 25 : 767-775, 2019 

243. Yao Y, Luo F, Tang C, Chen D, Qin Z, Hua W, et al. : Molecular subgroups？and B7-H4 expression levels predict responses to dendritic cell vaccines？in glioblastoma: an exploratory randomized phase II clinical trial. Cancer Immunol Immunother 67 : 1777-1788, 2018 

     상세보기

244. Yi Z, Prinzing BL, Cao F, Gottschalk S, Krenciute G : Optimizing EphA2-CAR T cells for the adoptive immunotherapy of glioma. Mol Ther？Methods Clin Dev 9 : 70-80, 2018 

     상세보기

245. Yin Y, Boesteanu AC, Binder ZA, Xu C, Reid RA, Rodriguez JL, et al. :？Checkpoint blockade reverses anergy in IL-13Rα2 humanized scFv-based？CAR T cells to treat murine and canine gliomas. Mol Ther Oncolytics？11 : 20-38, 2018 

246. Yvon ES, Burga R, Powell A, Cruz CR, Fernandes R, Barese C, et al. :？Cord blood natural killer cells expressing a dominant negative TGF-β？receptor: implications for adoptive immunotherapy for glioblastoma.？Cytotherapy 19 : 408-418, 2017 

247. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman？JD, et al. : Viral immune evasion due to persistence of activated T cells？without effector function. J Exp Med 188 : 2205-2213, 1998 

     상세보기

248. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS : EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer？Res 61 : 2301-2306, 2001 

249. Zhang C, Burger MC, Jennewein L, Genssler S, Schonfeld K, Zeiner P, et？al. : ErbB2/HER2-specific NK cells for targeted therapy of glioblastoma. J？Natl Cancer Inst 108 : djv375, 2016 

     상세보기

250. Zhang C, Oberoi P, Oelsner S, Waldmann A, Lindner A, Tonn T, et al. :？Chimeric antigen receptor-engineered NK-92 cells: an off-the-shelf cellular therapeutic for targeted elimination of cancer cells and induction of？protective antitumor immunity. Front Immunol 8 : 533, 2017 

251. Zhang JG, Eguchi J, Kruse CA, Gomez GG, Fakhrai H, Schroter S, et al. :？Antigenic profiling of glioma cells to generate allogeneic vaccines or？dendritic cell-based therapeutics. Clin Cancer Res 13(2 Pt 1) : 566-575, 2007 

252. Zhang R, Yuan F, Shu Y, Tian Y, Zhou B, Yi L, et al. : Personalized？neoantigen-pulsed dendritic cell vaccines show superior immunogenicity？to neoantigen-adjuvant vaccines in mouse tumor models. Cancer Immunol Immunother 69 : 135-145, 2020 

     상세보기

253. Zhao J, Cao Y, Lei Z, Yang Z, Zhang B, Huang B : Selective depletion of？CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide？is explained by reduced intracellular ATP levels. Cancer Res 70 : 4850-4858, 2010 

     상세보기

254. Zhao J, Lin Q, Song Y, Liu D : Universal CARs, universal T cells, and universal CAR T cells. J Hematol Oncol 11 : 132, 2018 

     상세보기

255. Zhao Z, Condomines M, van der Stegen SJC, Perna F, Kloss CC, Gunset G,？et al. : Structural design of engineered costimulation determines tumor？rejection kinetics and persistence of CAR T cells. Cancer Cell 28 : 415-428, 2015？ 

     상세보기